Secondment RECAP

In the last two years, our team completed some exciting experiments during our secondments in Dublin and Vienna, which have brought us one step closer to achieving our goal of researching cancer theranostic nanomaterials and cancer diagnostics. Through our experiments, we were able to gain new insights into the properties and behaviors of nanomaterials, which will help us to develop more effective cancer treatments and diagnostic tools. We also discovered some promising new nanomaterials that could have significant potential for cancer theranostics. Our secondments also gave us the chance to collaborate with researchers from around the world, exchanging ideas and knowledge that will help us continue to make progress in this field. It was an incredible experience that has only strengthened our commitment to advancing cancer research and treatment. Stay…
Read More
NANOFACTS in Portugal

NANOFACTS in Portugal

This February Dr. Nikola Knežević attended the International Meet on Pharmaceutics and Drug Delivery Systems (#Pharmameet2023) in Porto, Portugal. He delivered a keynote lecture entitled: "Cyclodextrin-Capped Mesoporous Silica-Based Nanomaterials for pH-Responsive Targeted Theranostics of Glioblastoma Multiforme".
Read More
NANOFACTS MEETING IN VIENNA!

NANOFACTS MEETING IN VIENNA!

After the summer meeting at the BioSense Institute, #nanofacts team members met last week in Vienna at the premises of the partner institution TU Wien. Seniors from Serbia and Ireland visited the Austrian partners, and reflected on the successes of the project so far while planning future postings and experiments with ESRs. 
Read More
New research paper is here!

New research paper is here!

Through the support from our project we published a new research paper in the journal Inorganics on the topic of using mesoporous silica nanoparticles for pH-responsive delivery of iridium metallotherapeutics and treatment of glioblastoma multiforme.Click on the link below to read the full paper: mesoporous silica nanoparticles for pH-responsive delivery of iridium metallotherapeutics and treatment of glioblastoma multiforme. pdf
Read More
NANOFACTS on Serbian national television

NANOFACTS on Serbian national television

Yesterday, NANOFACTS Project Coordinator, Dr. Nikola Knežević was a guest on Serbian national television presenting the project's objectives. Visit the following link to watch the TV show: https://www.youtube.com/watch?v=fccwBayWaSg (on Serbian only) 
Read More
NANOFACTS member was awarded the State Prize

NANOFACTS member was awarded the State Prize

On April 13, Prof. Dr. Peter Ertl from the Vienna University of Technology was awarded the State Prize for the Promotion of Alternative Methods to Animal Experiments for his research work by the Austrian Federal Ministry of Education, Science and Research. Prof. Dr. Peter Ertl is working on the development of biochips intended to replace animal testing in medicines. We are honored to have such great partners!
Read More
3rd secondment: BIOS to TCD

3rd secondment: BIOS to TCD

Mirjana Mundžić from BioSense Institute have started her visit and training at Trinity College Dublin. She is going to work on a research in application of nanotechnology for cancer treatment and imaging.
Read More
Interproject Collaboration

Interproject Collaboration

NANOFACTS project coordinator, Dr. Nikola Knežević, participated in the management committee meeting of the COST action NETPORE. The action aims to bridge the gap between fundamental developments and practical applications of technologies based on porous materials. Participation in this action enhances the networking possibilities of BIOS researchers in the area of application of porous nanomaterials.
Read More
2nd secondment: BIOS to TUW

2nd secondment: BIOS to TUW

Mila Djisalov and Teodora Knežić from BioSense Institute are on their extended stay visits at the Vienna University of Technology. Currently, they are participating in a workshop “Microfluidics and Cell Culture”. They are going to design microfluidic chips for cell culturing. The aim of their visit is the development of microfluidic chips for Glioblastoma cell culturing, as well as the development of cancer spheroid-on-a-chip technology for Glioblastoma Multiforme.
Read More